Alimera Sciences
ALIM
ALIM was delisted on the 13th of September, 2024.
41 hedge funds and large institutions have $42.9M invested in Alimera Sciences in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 5 closing their positions.
515% more call options, than puts
Call options by funds: $80K | Put options by funds: $13K
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
10% more capital invested
Capital invested by funds: $39M → $42.9M (+$3.94M)
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.01M |
| 2 |
AC
Armistice Capital
New York
|
+$713K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$55.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$37.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$259K |
| 2 |
Goldman Sachs
New York
|
-$129K |
| 3 |
Renaissance Technologies
New York
|
-$67.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$33K |
| 5 |
ICOA
Investment Centers of America
Bismarck,
North Dakota
|
-$32K |
ALIM Hedge Fund Activity: Q4 2017 in Review
41 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Alimera Sciences (ALIM) for Q4 2017, worth a combined $42.9M — up 10% from $39M a quarter earlier.
Fund positioning in ALIM was balanced in Q4 2017: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 8 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $4.01M. The largest seller was Deutsche Bank, exiting entirely with an estimated $259K sold.
- 41 institutional investors held Alimera Sciences (ALIM) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $42.9M of Alimera Sciences stock for Q4 2017, up 10% quarter-over-quarter.
- 5 funds opened new Alimera Sciences positions in Q4 2017 and 5 closed out, a net change of 0 holders.
- The largest Alimera Sciences buyer in Q4 2017 was Stonepine Capital Management, an estimated $4.01M added.
- The largest Alimera Sciences seller in Q4 2017 was Deutsche Bank, an estimated $259K sold.
Based on aggregated 13F filings for Q4 2017.